We continue to supply our medicines to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.

New questions and concerns will be raised as the pandemic changes and we want to keep you informed with updates on the supply of our medicines, answers for people who are taking them, and how to get in touch with us.

Assembly line of insulin pens

Currently, we are not experiencing any supply issues. We are well prepared for situations like this, and we have a storage policy that ensures long-term delivery.

This is important as we are dealing with vital medicines that patients all over the world depend on every day.

We are aware that health authorities and pharmacies are doing their best to ensure the availability of vital medicines during COVID-19, and we can assure you that our current stock levels are normal. As we continue to monitor the situation, we will share our updates.

Novo Nordisk laboratory technician

To protect the health and safety of our employees, we follow the advice and guidance from local health authorities. In some countries and communities where the risk of infection is still high, we are asking employees to work from home.

During these extraordinary working conditions, we are ensuring employees have support to keep active, work ergonomically from home and adopt to a digital workplace.

We are taking measures to keep employees working at our production sites safe and able to practice recommended social distancing when on the job.

HCP with patient, Novo Nordisk PIONEER study

We are continuing all of our already-initiated clinical trials and we do not expect significant delays in those that are close to finalisation. In the current situation, we are in close dialogue with trial investigators across the globe and we rely on their judgement to pause any ongoing trial recruitment and minimise patient visits to sites in order to coincide with regular medical care visits.

We also observe that trial follow-up is increasingly difficult, and we are working with relevant trial sites, investigators and authorities to find the best solutions in the situation. For ongoing trials, recruitment of new patients is negatively impacted, but gradually improving. It is now possible to initiate new trials in certain countries.

Novo Nordisk is supporting health authorities’ efforts in affected areas with several initiatives, including making donations, sharing raw materials for the production of hand sanitisers and opening up our labs to help with COVID-19 testing.

We are monitoring the global situation very carefully to ensure appropriate action can be taken as the situation develops.

We are aware that health authorities and pharmacies in some countries are doing their best to ensure medicine is always available for those who need it, but we can assure you that our current stock levels are normal.

This means that there might be limits to the amount of medicine or number of devices a patient is able to get at any one time. It is important to collect your medicine or devices as per normal requirements, so that all people living with diabetes and other chronic diseases have access to their essential medicine.

We are in close contact with our partners, including health authorities and pharmacies, to monitor their inventory levels.

The situation is continually evolving, but currently we are not experiencing any supply constraints. We are well prepared for situations like this and have an inventory policy that serves long-term supply. This is important since our medicines are needed every day by patients all over the world. 

At Novo Nordisk, when conducting clinical trials, our priorities are patient safety and clinical trial integrity. We are continuing all of our already-initiated clinical trials and we do not expect significant delays in those that are close to finalisation.

In the current situation, we are in close dialogue with trial investigators across the globe and we rely on their judgment to pause any ongoing trial recruitment and minimise patient visits to sites in order to coincide with regular medical care visits.

We also observe that trial follow-up is increasingly difficult, and we are working with relevant trial sites, investigators and authorities to find the best solutions in the situation. To reflect the current strain on the healthcare system, no new trials will be initiated.

To protect the health and safety of our employees, we follow the advice of local health authorities to ensure safe working conditions. 

For employees still working remotely, we are ensuring they have support to keep active, work ergonomically from home and adapt to a digital workplace.

We are taking measures to provide safe working conditions at our production sites and to practice recommended social distancing practices when on the job. We are asking only those employees for whom COVID-19 is not considered a health risk to be in the office or factory.

If you have any questions or concerns about the availability or affordability of our medicines during the COVID-19 pandemic, please contact our local office in your country.

Click here get an overview of our global offices